Yeast tRNAPhe expressed in human cells can be selected by HIV-1 for use as a reverse transcription primer  by Kelly, Nathan J & Morrow, Casey D
Yeast tRNAPhe expressed in human cells can be selected by HIV-1
for use as a reverse transcription primer
Nathan J. Kellya and Casey D. Morrowb,*
a Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
b Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Received 18 October 2002; returned to author for revision 3 March 2003; accepted 7 March 2003
Abstract
All naturally occurring human immune deficiency viruses (HIV-1) select and use tRNALys,3 as the primer for reverse transcription.
Studies to elucidate the mechanism of tRNA selection from the intracellular milieu have been hampered due to the difficulties in
manipulating the endogenous levels of tRNALys,3. We have previously described a mutant HIV-1 with a primer binding site (PBS)
complementary to yeast tRNAPhe (psHIV-Phe) that relies on transfection of yeast tRNAPhe for infectivity. To more accurately recapitulate
the selection process, a cDNA was designed for the intracellular expression of the yeast tRNAPhe. Increasing amounts of the plasmid
encoding tRNAPhe resulted in a corresponding increase in levels of yeast tRNAPhe in the cell. The yeast tRNAPhe isolated from cells
transfected with the cDNA for yeast tRNAPhe, or in the cell lines expressing yeast tRNAPhe, were aminoacylated, indicating that the
expressed yeast tRNAPhe was incorporated into tRNA biogenesis pathways and translation. Increasing the cytoplasmic levels of tRNAPhe
resulted in increased encapsidation of tRNAPhe in viruses with a PBS complementary to tRNAPhe (psHIV-Phe) or tRNALys,3 (wild-type
HIV-1). Production of infectious psHIV-Phe was dependent on the amount of cotransfected tRNAPhe cDNA. Increasing amounts of plasmids
encoding yeast tRNAPhe produced an increase of infectious psHIV-Phe that plateaued at a level lower than that from the transfection of the
wild-type genome, which uses tRNALys,3 as the primer for reverse transcription. Cell lines were generated that expressed yeast tRNAPhe
at levels approximately 0.1% of that for tRNALys,3. Even with this reduced level of yeast tRNAPhe, the cell lines complemented psHIV-Phe
over background levels. The results of these studies demonstrate that intracellular levels of primer tRNA can have a direct effect on HIV-1
infectivity and further support the role for PBS-tRNA complementarity in the primer selection process.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
A common feature of all retroviruses is the use of a
cellular tRNA as a primer for reverse transcription in which
the viral RNA genome is replicated into DNA prior to
integration in the host cell chromosome (Gilboa et al., 1979;
Mak and Kleiman, 1997). The initiation of reverse tran-
scription occurs at a region in the viral genome designated
as the primer binding site (PBS) (Gilboa et al., 1979; Var-
mus and Swanstrom, 1982). The PBS is complementary to
the 3-terminal nucleotides of the cellular tRNA molecule
used for initiation (Gilboa et al., 1979; Varmus and Swan-
strom, 1982). Retroviruses have evolved to use specific
tRNAs in reverse transcription (Mak and Kleiman, 1997).
For example, all lentiviruses, including human immunode-
ficiency virus, select tRNALys,3 for reverse transcription
(Mak and Kleiman, 1997). Even though HIV-1 exclusively
uses tRNALys,3, the virus has the capacity to use a wide
variety of tRNAs if the PBS is altered to be complementary
to the 3 18 nucleotides of the alternative (non-tRNALys,3)
tRNA (Das, Klaver, and Berkhout, 1995; Kang, Wakefield,
and Morrow, 1996; Li et al., 1994; Wakefield, Wolf, and
Morrow, 1995). After short-term replication in culture
though, all of these viruses revert back to utilize tRNALys,3
as a primer. Several viruses have been engineered to utilize
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alternative tRNA primers by introducing additional muta-
tions in the U5 A-rich loop complementary to the anticodon
region of the alternative tRNA (Kang and Morrow, 1999;
Kang, Zhang, and Morrow, 1999; Wakefield, Kang, and
Morrow, 1996; Zhang et al., 1996). Even with these muta-
tions, not all anticodon-PBS combinations resulted in the
stable utilization of alternative tRNA primers (Kang, Wake-
field, and Morrow, 1996). Thus, the features for selection of
the tRNA primer and the maintenance of the PBS comple-
mentary to tRNALys,3 have not been completely elucidated.
One of the more difficult questions to address in the
selection process has been the role that availability of the
tRNA primer plays in the selection process, since it is
difficult to manipulate levels of tRNAs in eukaryotic cells.
To address this question we have constructed a complemen-
tation system for HIV-1 using a provirus in which the PBS
has been altered to be complementary to yeast tRNAPhe (Yu
and Morrow, 1999; Yu and Morrow, 2000; Yu and Morrow,
2001). Previous studies from this laboratory have shown
that the infectivity of this virus requires cotransfection of
yeast tRNAPhe that can be prepared by in vitro transcription
of the tRNA cDNA. Using this system, we have begun to
dissect the elements of the tRNA molecule that is required
for HIV-1 infectivity. Our previous studies clearly show that
certain elements within the tRNA, such as the D-loop, are
not necessary for HIV-1 infectivity, whereas other elements
in the TC-loop of the tRNA are essential (Yu and Morrow,
1999, 2000, 2001).
Our studies to date have used in vitro transcribed tRNA
to complement the defective HIV-1 proviral genome. Al-
though this system has proven useful for delineation of
some of the features of the tRNA for essential for HIV-1
replication, it does not reflect elements of the biogenesis
common for all tRNAs. Following transcription of the
tRNA gene by RNA polymerase III, the pre-tRNA under-
goes 5 and 3 processing. Additional posttranscriptional
modifications include modified nucleotides and CCA addi-
tion (Wolin and Matera, 1999). Recent studies have found
that aminoacylation can occur in the nucleus and may pro-
mote rapid export of the tRNA to the cytoplasm (Arts and
Le Grice, 1998; Lund and Dahlberg, 1998). Following
transport, the tRNA is “channeled” into protein synthesis
(Gorlich and Kutay, 1999; Wolin and Matera, 1999). It has
been estimated that approximately 30 intracellular proteins
interact with the tRNAs during synthesis and use in trans-
lation. The amount of free tRNA (i.e., nonaminoacylated) is
vanishingly low in cells (Ho and Kan, 1987; Wolin and
Matera, 1999).
In the current study, we have examined whether yeast
tRNAPhe can be expressed from its natural promoter in
eukaryotic cells and if the endogenously expressed tRNAPhe
can complement the infectivity of a proviral genome with a
PBS complementary to yeast tRNAPhe. We have utilized
cotransfection to demonstrate that the yeast tRNAPhe ex-
pressed using its cognate promoter can effectively comple-
ment HIV-1 infectivity up to levels approaching that ob-
tained for wild-type genomes with a PBS complementary to
tRNALys,3. We have also constructed cell lines which ex-
press yeast tRNAPhe and have shown that the majority of the
tRNAPhe is aminoacylated, indicating its competency for
entry into the normal tRNA biogenesis pathways within
mammalian cells. Our studies demonstrate a correlation
between the quantity of endogenously expressed yeast
tRNAPhe and the amount of infectious virus produced in
these cells. The results of our studies are discussed with
respect to the role that the interaction between PBS and
tRNA plays in selection of the tRNA primer required for
HIV-1 replication.
Results
Intracellular expression of yeast tRNAPhe
A yeast tRNAPhe gene was constructed using PCR ex-
tension with oligonucleotides designed to include the A and
B box intragenic pol III promoters, thymidine nucleotides at
the 3 terminus necessary for pol III termination, and a 5
leader sequence (Fig. 1). Following PCR, the product was
cloned into a plasmid and the DNA insert was completely
sequenced. We found that many of the tRNA clones were
genetically unstable following propagation in Escherichia
coli, which was overcome, for the most part, by growth at
low temperatures (Kelly and Morrow, unpublished obser-
vations). The majority of the mutations routinely observed
were either point mutations or deletions within the A box,
rendering the intragenic pol III promoter inactive. We were,
however, able to obtain a complete yeast tRNAPhe expres-
sion cassette after screening of several clones. The yeast
tRNAPhe gene was also subcloned into a vector which al-
lows for amplification in cells expressing the SV40 T anti-
gen and was identified as pCI-Phe; again, the complete
tRNA gene was sequenced prior to use in the complemen-
tation assay.
To determine if we would express tRNAPhe in cells, we
collected total RNA from 293T cells transfected with in-
creasing amounts of pCI-Phe. An oligonucleotide probe
specific yeast tRNAPhe was used; human tRNAPhe differs
from yeast tRNAPhe at 17 positions (Nazarenko et al.,
1992), allowing for high specificity of oligo probes compli-
mentary to yeast tRNAPhe. Increasing concentrations of
transfected pCI-Phe resulted in a corresponding increase in
levels of yeast tRNAPhe in 293T cells (Fig. 2A).
Yeast tRNAPhe expressed in mammalian cells is
aminoacylated
One of the bench marks for functional tRNA in the cell
is the capacity to undergo aminoacylation. This process
requires appropriate 5 or 3 processing, CCA addition and
interaction with the appropriate aminoacyl-tRNA synthetase
(Wolin and Matera, 1999). In addition, recent studies have
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shown that aminoacylation can facilitate rapid transport
from the nucleus to the cytoplasm (Lund and Dahlberg,
1998). Previous studies have shown that yeast tRNAPhe is
an excellent substrate for mammalian phenylalanyl-tRNA
synthetase and aminoacylation of yeast tRNAPhe readily
occurs in vitro with the mammalian enzyme (Zakharova,
Kotenko Iu, and Lavrik, 1990). The capacity of yeast
tRNAPhe to be processed and aminoacylated within mam-
malian cells has not been previously described. Since yeast
tRNAPhe was being overexpressed after transfection of plas-
mid DNA, it was necessary to show that the foreign tRNA
was being aminoacylated and complementation of an HIV-1
with a PBS complementary to yeast tRNAPhe did not result
from selection of tRNA that was unable to enter the normal
mammalian tRNA biogenesis pathways. To test for amino-
acylation of the yeast tRNAPhe in mammalian cells, we
analyzed the tRNAPhe from transfected cells by Northern
blotting of total cellular RNA separated on a polyacryl-
amide gel buffered at pH 5 (Ho and Kan, 1987). For com-
parison, we also analyzed endogenous levels of aminoacy-
lation for tRNALys,3. We found that the vast majority of the
tRNALys,3 isolated was aminoacylated (Fig. 2B); this result
is consistent with what is known about the steady-state
levels of tRNA in mammalian cells (Ho and Kan, 1987;
Wolin and Matera, 1999). Most importantly, we also found
that the majority of the yeast tRNAPhe expressed from
transfection of plasmids was aminoacylated. Collectively,
these results show that the yeast tRNAPhe derived from
transfection is aminoacylated and thus accesses the biosyn-
thetic pathways and translational machinery of the cell.
Yeast tRNAPhe is incorporated into HIV-1 virions
independent of the primer binding site
In previous studies, we have described an HIV-1 proviral
genome in which the PBS has been altered to correspond to
the 3 18 terminal nucleotides of yeast tRNAPhe (Yu and
Morrow, 1999, 2000, 2001). This defective proviral ge-
nome, designated psHIV-Phe, has an expression cassette
consisting of the SV40 early promoter and a gene encoding
xanthine–guanosine phosphoribosyl transferase (gpt) in
place of a deleted env gene. Pseudoviruses were derived
from cotransfection of psHIV-Phe and pLGRNL, which
encodes the VSV-G protein.
As a first step in the characterization of our system, we
analyzed HIV-1 virions for the incorporation of yeast
tRNAPhe. To do this, we cotransfected psHIV-Phe or
pHgWT (a plasmid containing the wild-type HIV-1 ge-
nome) along with increasing concentration of pCI-Phe. The
amount of virus from the transfected cells was quantitated
by the p24 antigen-capture ELISA. Equivalent amounts of
p24 associated RNA were blotted onto a positively charged
nylon membrane and probed for tRNALys,3 or tRNAPhe. In
general, the amounts of tRNALys,3 detected in virions for
psHIV-Phe or psHGWT were not influenced by the coex-
pression of tRNAPhe (Fig. 3A). This result is not entirely
unexpected since in previous studies we have found HIV-1
that use an alternative tRNA primer (tRNAHis) had a similar
profile of tRNALys1,2/tRNALys,3 as did the wild-type virus
(Zhang et al., 1996). Thus, the incorporation of tRNA into
HIV-1 virions is not dependent on complementarity with the
Fig. 1. The defective HIV-1 proviral genome and engineered yeast tRNAPhe gene. (A) Schematic of the engineered yeast tRNAPhe gene. The RNA polymerase
III intragenic promoter elements are designated A and B boxes. The 5 leader sequence and 3 sequence containing restriction enzyme sites are highlighted
in gray. The transcription initiation and termination points are noted. The intron present within the native yeast tRNAPhe gene was not included in the
construct. (B) The psHIV-Phe proviral genome. The defective psHIV-Phe proviral genome contains a PBS complementary to yeast tRNAPhe (PBSPhe). The
env gene of HIV was substituted by the xanthine-guanosine phosphoribosyl transferase (gpt) gene, under the control of SV40 early promoter. To generate
pseudoviruses, this plasmid was cotransfected with the plasmid encoding VSV-G protein (pLGRNL) either with or without a plasmid expressing yeast
tRNAPhe. Successful infection of cells with the pseudoviruses confers resistance to mycophenolic acid.
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PBS. In support of this, we found that the increased cyto-
plasmic expression of tRNAPhe resulted in an increase in
tRNAPhe in virions derived from either psHIV-Phe or
pHgWT (Fig. 3B). The incorporation of tRNAPhe appeared
to reach a plateau beginning with 1 g of cotransfect pCI-
Phe. Thus, the results of our studies demonstrate the capac-
ity to increase the cytoplasmic amounts of tRNAPhe that
results in the increased incorporation into HIV-1 virions.
There is no inherent defect in yeast tRNAPhe for incorpo-
ration into virions and, similar to tRNALys,3, tRNAPhe can
be incorporated into virions regardless of complementarity
with the PBS.
Complementation of psHIV-Phe infectivity
The most critical aspect of our system is to ascertain
whether the expressed tRNAPhe will complement infectivity
of the defective virus. In our previous studies, we found that
cotransfection of psHIV-Phe, pLGRNL, and in vitro-gener-
ated yeast tRNAPhe resulted in infectious virus as judged by
the capacity to convert HeLa cells to resistance to myco-
phenolic acid. The colony forming unit (cfu) of infectious
viruses generated following cotransfection was substantially
above background levels seen in the absence of yeast
tRNAPhe but significantly less than observed for viruses in
which the PBS was complementary to tRNALys,3. The rea-
son for the low complementation was not apparent. One
possibility was that cotransfection of DNA (proviral plas-
mid and plasmid encoding VSV-G) and the synthetic
tRNAPhe was low; this seemed unlikely because we were
readily able to detect the transfected tRNAPhe at various
times posttransfection. A more likely possibility is that the
tRNA selection process is coordinated with proviral RNA
synthesis and tRNA biogenesis. To address this issue, we
developed a system whereby both the proviral genomes and
tRNA cDNAs were cotransfected. To determine if plasmids
encoding yeast tRNAPhe would rescue psHIV-Phe, we per-
formed the cotransfection using a variety of plasmid con-
centrations (Fig. 4). A dose response was established for the
quantities of tRNA expressing plasmids by determining the
titer of infectious virus that correlated with the numbers of
drug-resistant colonies. In the case of the yeast tRNAPhe
cloned into the TA vector, we found a linear increase in the
number of colonies with the increasing amounts of trans-
fected pTA-Phe, demonstrating that under these conditions
the production of infectious virus was dependent on the
amount of tRNAPhe expressing plasmid. We next analyzed
the production of infectious virus using the plasmid pCI-
Fig. 3. Virion association of tRNAPhe. (A) Northern blot of total RNA
collected from viruses produced by cotransfection of psHIV-Phe or
pHgWT with pLGRNL and varied concentrations of pCI-Phe into 293T
cells. Virions were normalized by p24 and 2000 pg p24 were used for RNA
isolation. (Lane 1) Total virion associated RNA obtained from viruses
produced by cotransfection of 0 g pCI-Phe, (lane 2) total virion associated
RNA obtained from viruses produced by cotransfection of 0.1 g pCI-Phe,
(lane 3) total virion associated RNA obtained from viruses produced by
cotransfection of 1.0 g pCI-Phe, and (lane 4) total virion associated RNA
obtained from viruses produced by cotransfection of 3.0 g pCI-Phe. The
Northern blot was probed for tRNALys,3. (B) Northern blot from panel A
probed for yeast tRNAPhe.
Fig. 2. Expression of tRNAPhe in mammalian cells. (A) Northern blot of
total RNA collected from 293T cells after transfection with varied con-
centrations of pCI-Phe. (Lane 1) Two micrograms of total RNA from 293T
cells transfected with 0 g pCI-Phe, (lane 2) 2 g total RNA from 293T
cells transfected with 0.1 g pCI-Phe; (lane 3) 2 g total RNA from 293T
cells transfected with 1.0 g pCI-Phe, (Lane 4) 2 g total RNA from 293T
cells transfected with 2.0 g pCI-Phe, and (lane 5) 2 g total RNA from
293T cells transfected with 3.0 g pCI-Phe. The Northern blot was probed
for yeast tRNAPhe. (B) Aminoacylation of tRNAs. Northern blot analysis
of cytoplasmic yeast tRNAPhe and tRNALys,3 from cells transfected with
pTA-Phe. All lanes contain 2 g cytoplasmic RNA isolated under acidic
conditions. The RNA loaded in lanes 2 and 4 were adjusted to pH 9.0 and
incubated at 37°C for 1 h to serve as the deacylated controls. The migration
of aminoacylated tRNA and deacylated control tRNA are denoted as AA
and DA respectively. Lanes 1 and 2 were probed for yeast tRNAPhe and
lanes 3 and 4 were probed for tRNALys,3. The exposure times for each blot
were the same. Phosphorimage analysis of the AA versus DA in lanes 1
and 3 revealed a ratio of greater that 99 to 1 indicating that the vast
majority of the yeast tRNAPhe and tRNALys,3 were isolated from the cells
was aminoacylated.
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Phe; in this case, the tRNAPhe gene is identical to that in
pTA-Phe, but pCI-Phe contains an SV40 origin of replica-
tion to allow amplification in 293T cells. Using the same
experimental conditions, we routinely found that greater
number of drug-resistant colonies were obtained if pCI-Phe
was substituted for pTA-Phe, presumably due to the fact
that the 293T cells provide the necessary conditions for
replication of the transfected plasmids containing the SV40
origin of replication. The amount of infectious virus reached
a plateau of approximately 2700 colonies/ng p24 beginning
at 1 g of cotransfected pCI-Phe. Using pCI-Phe with
psHIV-Phe, we found that the number of drug-resistant
colonies approached 50% of that seen for the transfection of
pHgWT, where the PBS is complementary to tRNALys,3 and
the production of infectious virus is dependent on endoge-
nous levels of tRNALys,3. The level of complementation of
psHIV-Phe with either plasmid (pCI-Phe or pTA-Phe) was
greater than 40-fold above that previously reported for
complementation with in vitro transcribed yeast tRNAPhe.
Interestingly, the amounts of infectious virus plateaued at 1
g of pCI-Phe cotransfected with psHIV-Phe, whereas the
amount of tRNAPhe produced increased following cotrans-
fection with 2 g pCI-Phe and psHIV-Phe (Fig. 4). Collec-
tively, the results of these studies suggest that the HIV
primer selection process can be saturated by increased
amounts of expressed tRNA following transfection of
cDNAs encoding the priming tRNA.
Generation of cell lines expressing yeast tRNAPhe and
complementation of psHIV-Phe
The ability to transfect plasmids encoding yeast tRNAPhe
for complementation of psHIV-Phe prompted us to deter-
mine whether we could generate cell lines for continuous
expression of yeast tRNAPhe. Our strategy for generation of
cell lines involved the linearization and transfection of pCI-
Phe encoding yeast tRNAPhe into 293 cells. Also present on
the pCI-Phe vector is the neo gene that allowed for selection
in the presence of G418; a control cell line was also devel-
oped by transfection of pCIneo that did not contain the
tRNAPhe gene. Following selection with G418, individual
cell clones were isolated and the cell numbers amplified. In
general, we found that transfection of pCI-Phe gave rela-
tively few colonies; this was not due to transfection since
transfection of pCI gave rise to numerous colonies. Further-
more, many of the cell colonies obtained following trans-
fection with pCI-Phe grew for a short time following clon-
ing, but subsequently died. After numerous trials, we did
isolate two stable cell lines following transfection with
pCI-Phe. The cells grew similar to the control cells and were
used to test for complementation of psHIV-Phe. Following
cotransfection with psHIV-Phe and pLGRNL, the viruses
produced were quantitated by p24 and used to reinfect HeLa
H1 cells followed by selection with mycophenolic acid.
Again, numbers of drug-resistant colonies reflect the titer of
infectious virus. Both cell lines complemented psHIV-Phe
at low levels, representing approximately 5% of that ob-
served for complementation of the provirus (pHgWT) with
PBS complementary to tRNALys,3 (Fig. 5A). This was not
due to differences in transfection efficiencies between the
different cell lines, since we used these same lines for
transfections of the proviruses with a PBS complementary
tRNALys,3 (pHgWT) and produced comparable levels of
infectious virus obtained from transfection of 293 cells (data
not shown).
To further investigate the reason for the low-level
complementation in the cell lines, we compared the steady-
state levels of yeast tRNAPhe with that of tRNALys,3. Total
cellular RNA preparations from the cell lines were sub-
jected to Northern blot analysis using oligonucleotide
probes specific for yeast tRNAPhe or tRNALys,3. In this case,
we found that we could readily detect tRNALys,3 in the RNA
preparations from both cell lines (Fig. 5B). However, ana-
lyzing the same RNA samples for the presence of yeast
tRNAPhe revealed that the tRNAPhe was present at a sub-
stantially lower amount than tRNALys,3. Quanitation of the
blots by phosphorimaging revealed that the amount of yeast
tRNAPhe was approximately 0.1% of that for tRNALys,3.
Further analysis revealed that the ratio of aminoacylated/
free for tRNAPhe in these cell lines was similar to that found
for expression of tRNAPhe from plasmids (data not shown).
Thus, using our selection scheme for cell lines producing
yeast tRNAPhe, we had most likely selected for cells which
produced yeast tRNAPhe but at a substantially lower level
Fig. 4. Complementation of psHIV-Phe by plasmids expressing yeast
tRNAPhe. Numbers of drug-resistant colonies derived from infection of
pHGWT pseudoviruses are represented as diamonds. Viruses were pro-
duced in 293T cells after cotransfection of pHGWT (PBSLys,3), pLGRNL,
and pTAphe. Plasmids pHGWT and pLGRNL were kept constant at 1g
while pTA-Phe concentration was varied as described in the figure. The
numbers of drug-resistant colonies derived from infection of psHIV-Phe
pseudoviruses complemented by yeast tRNAPhe expressed from designated
quantities of cotransfected pCI-Phe are represented as triangles. Note that
the pCI-Phe contains an SV40 origin of replication, allowing plasmid
amplification in 293T cells. The numbers of drug-resistant colonies derived
from infection of psHIV-Phe pseudoviruses complemented by yeast
tRNAPhe expressed designated quantities of cotransfected pTA-Phe are
represented as squares. The pTA-Phe vector does not contain the SV40
origin of replication. The data is from three independent transfections for
each point with standard deviations.
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than that observed for tRNALys,3. Previous reports have
indicated that overexpression of tRNAs can lead to cellular
toxicity and may explain the inadvertent selection of low-
producing cell lines (Doerig et al., 1988; Hudziak, Schless-
inger, and Ullrich, 1987; Laski et al., 1989). What is most
remarkable is that even with the low levels of yeast
tRNAPhe, we could easily detect complementation of
psHIV-Phe over background levels, indicating that high
concentrations of primer need not be present within the
cytoplasm for selection by HIV-1 for use in reverse tran-
scription.
Discussion
In this report, we have used a novel complementation
system that uses yeast tRNAPhe to complement a defective
viral genome with a PBS complementary to yeast tRNAPhe.
The in vivo expression of yeast tRNAPhe in mammalian
cells was accomplished by constructing an expression cas-
sette in which the tRNA gene was expressed using its
native, intragenic RNA polymerase III promoter. We found
that most of the yeast tRNAPhe is aminoacylated, suggesting
that the yeast tRNAPhe accessed the tRNA biogenesis and
intracellular pathways for use in translation. The levels of
virion associated yeast tRNAPhe was examined and found to
correlate with levels of intracellular yeast tRNAPhe; at
higher concentrations of intracellular tRNAPhe, we observed
no proportional increase in virion-associated tRNAPhe. Im-
portantly, yeast tRNAPhe was also incorporated into wild-
type HIV-1 virions that contained a PBS complementary to
tRNALys,3. We found that the level of infectious virus ob-
tained following transfection was proportional to the
amount of yeast tRNAPhe produced within the cell; although
at high concentrations of intracellular yeast tRNAPhe, we
observed no increase in infectious virus, indicating that we
had possibly saturated the selection mechanism. Finally,
cells lines were isolated that expressed low levels of yeast
tRNAPhe compared to tRNALys,3. Even with the low levels
of tRNAPhe (relative to tRNALys,3), the cells lines comple-
mented psHIV-Phe above background levels.
The complementation system described in this report is
unique in that the production of infectious HIV-1 relies
solely on the presence of yeast tRNAPhe. In previous studies
we found this virus was noninfectious, owing to the inability
of mammalian tRNAPhe to be selected by the virus and used
in reverse transcription (Wakefield and Morrow, 1996;
Wakefield, Rhim, and Morrow, 1994). To restore infectiv-
ity, yeast tRNAPhe generated from in vitro transcription was
cotransfected with the proviral genome. The in vitro tran-
scribed tRNAPhe was shown to complement at levels similar
to that for tRNAPhe isolated from yeast, suggesting that
Fig. 5. Cell lines expressing yeast tRNAPhe rescue psHIV-phe. (A) 293 cells were transfected with linearized pCI-Phe that contains the gene encoding
neomycin resistance under control of the SV40 early promoter. The cells were selected by addition of G418 to the culture media and allowed to expand into
colonies. Two stable colonies (24A and 29B) were cloned and expanded. As a control, 293 cells were transfected with pCI-neo (vector with no insert) and
single cell colonies resistant to G418 were cloned and expanded. The numbers of drug-resistant colonies derived from infection of the psHIV-Phe
pseudoviruses complemented by yeast tRNAPhe expressed in cell lines shown as percentage of the number of drug-resistant colonies derived from infection
of the pHgWT (PBSLys) pseudoviruses obtained from the same cell lines. The percentage was calculated by dividing the mean number of colonies produced
from transfection with psHIV-Phe by the mean number of colonies resulting from the transfection of pHgWT within the same cells. The means used for the
calculation of the percentage were derived from 3 independent transfections. (B) Northern blot analysis of total RNA from two yeast tRNAPhe producing cell
lines and a negative control cell line that does not express yeast tRNAPhe. The samples in lanes 1–5 were probed for yeast tRNAPhe, whereas lanes 6–9 were
probed for tRNALys,3. The order of the lanes are as follows: Lanes 1 and 8 contain 30 g total RNA from cell line 24A; lanes 2 and 9 contain 30 g total
RNA from cell line 29B; Lanes 3 and 7 contain 30 g total RNA from normal 293 cells; lane 4 is blank; lanes 5 and 6 contain in vitro transcribed yeast
tRNAPhe. The percentage of yeast tRNAPhe to tRNALys,3 was on the order of 0.1% as determined by phosphorimaging of the samples in lanes 1 and 2
compared to the same samples probed for tRNALys,3 (lanes 8 and 9). The arrow denotes the migration of tRNAPhe and tRNALys,3.
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modified nucleotides in tRNAPhe are not essential for
complementation (Yu and Morrow, 1999, 2000, 2001). Us-
ing this system, we were able to dissect the critical structural
elements of the tRNA which are essential for HIV-1 to
select and utilize as a primer for HIV-1 reverse transcrip-
tion. However, this system relied on the introduction of in
vitro transcribed tRNAPhe into the cytoplasm by transfec-
tion. It is unlikely that this tRNA would be recognized by
the translational machinery of the cell (Gorlich and Kutay,
1999; Wolin and Matera, 1999). In fact, previous studies
have shown that tRNAs exogenously added to the cyto-
plasm were not aminoacylated, leading to the conclusion
that the tRNA must be channeled into the protein synthesis
machinery at some step(s) during tRNA biogenesis. Thus, it
was possible that endogenously expressed tRNAPhe might
not complement the defective HIV-1, since it might be
incorporated into the translational machinery of the cell. To
understand how the availability of a tRNA that is competent
for entry into the translational machinery would affect the
capacity to be selected by HIV-1 for reverse transcription,
we refined our system so that the expression of the yeast
tRNAPhe would occur from its cognate promoter following
transfection in mammalian cells. If our system is to accu-
rately reflect elements of the HIV-1 primer tRNA selection
process, we would predict that the majority of the yeast
tRNAPhe would be aminoacylated. Indeed, the vast majority
of tRNALys,3 and expressed tRNAPhe were aminoacylated.
Consistent with this result, previous studies have shown that
yeast tRNAPhe is a substrate for the mammalian phenylala-
nyl-tRNA synthetase in vitro and based on this study can
also be efficiently aminoacylated in vivo (Zakharova, Ko-
tenko Iu, and Lavrik, 1990). Most importantly, we found
that the ratio of tRNAPhe that was aminoacylated relative to
free tRNAPhe was comparable to that of tRNALys,3. Thus,
the tRNAPhe expression appears to reflect critical elements
of the tRNA biogenesis.
Increasing concentrations of intracellular yeast tRNAPhe
was associated with increased encapsidation into the virion.
Overexpression of tRNALys,3 has also has been reported to
be associated with increased incorporation into HIV-1 viri-
ons, although endogenous levels of tRNALys,3 precluded the
determination of whether the excess tRNALys,3 expressed
from transfection was actually used as a primer (Gabor et
al., 2002). Although an association with aminoacylation of
tRNA and incorporation into virion has been found, an
absolute relationship between the encapsidation of a tRNA
and its use in reverse transcription has not been completely
established (Javanbakht et al., 2002). We found that
tRNAPhe was encapsidated into wild-type virions that con-
tain a PBS complementary to tRNALys,3 virions. Previous
studies from our laboratory have demonstrated that an
HIV-1 that selectively uses tRNAHis for reverse transcrip-
tion during multiple rounds of replication maintains the
same complement of tRNALys,3/tRNALys1,2 as does the
wild-type virus; however, there was not a selective enrich-
ment of tRNAHis (Zhang et al., 1996). Consistent with these
studies, alteration of the PBS to be complementary to
tRNALys1,2, which is enriched in the virion, does not result
in HIV-1 using this tRNA for replication unless additional
mutations are made in the U5 region (Kang, Zhang, and
Morrow, 1999). Collectively the results of these studies
suggest that the encapsidation of tRNA might not be strictly
coupled with the selection for use as a primer in reverse
transcription. Additional studies using this complementa-
tion system where we can control the levels of the primer
tRNA expression will help to clarify the relationship be-
tween tRNA encapsidation and use in replication.
The ability to shift the use of HIV-1 from tRNALys,3 to
tRNAPhe by changing the PBS highlights the role that PBS:
tRNA complementarity plays in the selection process. To
date, the systems used to study HIV-1 primer selection have
relied on the overexpression of wild-type or mutant
tRNALys,3 (Gabor et al., 2002; Huang et al., 1994; Javan-
bakht et al., 2002). However, this approach does not account
for background levels of endogenous tRNALys,3 and the
effect of overexpression on the physiology of the cell. The
complementation system described in this study relies on
the expression of yeast tRNAPhe and, as we have shown, the
increase in the production of infectious virus correlates with
increases in cytoplasmic tRNAPhe expression with little to
no background infectious virus. One element of the selec-
tion process that is now clear from our studies is that the
virus must have either evolved mechanisms to identify the
low levels of free tRNA in the cell for selection of the tRNA
primer or is capable of capturing tRNA that is actively
involved in protein synthesis. To select free tRNA, HIV-1
must have evolved a process to select the primer from a
vanishingly small intracellular pool of tRNAs. In support of
the alternative, that HIV-1 can select tRNAs that have been
channeled into translation, we observed complementation
from cell lines that produced yeast tRNAPhe at levels 0.1%
of that of tRNALys,3. Even when expressed at these low
levels, the majority of yeast tRNAPhe was aminoacylated,
indicating that the tRNA was sequestered within the chan-
neled tRNA cycle revolving around translation. Any model
for the selection of the tRNA primer needs to take into
account the fact that the majority of the tRNA in the cell, at
any one time, is involved in protein synthesis (Negrutskii
and Deutscher, 1991; Negrutskii, Stapulionis, and Deut-
scher, 1994; Sivaram and Deutscher, 1990; Stapulionis and
Deutscher, 1995; Wolin and Matera, 1999). The selection
process may involve protein–tRNA complexes. Interest-
ingly, several proteins that are responsible for channeling
tRNAs through translation are also found within the HIV-1
virion, including EF1A and lysyl-tRNA synthetase (Cen et
al., 2001; Cimarelli and Luban, 1999). Future studies using
the system described in this report will help to elucidate the
role of protein–tRNA complexes in the tRNA selection
process for HIV-1. Ultimately, these studies could lead to
the development of new therapeutic strategies to disrupt this
process and inhibit HIV replication.
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Materials and methods
Tissue culture
The 293, 293T, and HeLa H1 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) plus 10%
fetal calf serum (FCS) and 1% antibiotic–antimycotic
(Gibco/BRL, Gaithersburg, MD) (Zhang et al., 1998). Cell
lines producing yeast tRNAPhe were maintained in DMEM
plus 15% fetal calf serum, 1% antibiotics, and 0.5 mg/ml
G418 sulfate (Gibco/BRL, Gaithersburg, Maryland).
Construction of yeast tRNAPhe plasmids and cell lines
Two oligonucleotides (5-TCTAGAATCGGATCCGTA-
TACTCTTTCTTCAACAATTAGAGCTC GCGGATTTAG-
CTCAGTTGGGAGAGCGCCAGACTGAAGATCTG-3
and 5-GGATCCATGGTA CCCAAAAAATGCGAATTCT-
GTGGATCGAACACAGGACCTCCAGATCTTCAGTCTG-
3) were used to construct the yeast tRNAPhe gene via PCR
extension. The PCR product was then ligated into the pGEM-T
Easy vector (Promega, Madison, WI). The resultant vector,
pTAPhe, containing the yeast tRNAPhe expression cassette was
digested with NaeI and NdeI generating a 543-bp fragment con-
taining the transcriptional unit. The 543-bp fragment was cloned
into pCI-neo (Promega) that had been digested with SmaI and
NdeI; the plasmid was identified as pCI-Phe. All restriction en-
zymes were supplied by New England Biolabs (Beverly, MA).
The correct sequence of the yeast tRNAPhe transcriptional unit
contained in both pCI-Phe and pTA-Phe were verified by se-
quencing with the M13 Reverse Sequencing Primer (Promega).
Cell lines expressing yeast tRNAPhe were constructed by CaPO4
transfection of 293 cells with pCI-Phe that had been linearized by
HpaI digestion; the CaPO4 transfection kit was obtained from
(Stratagene, San Diego, CA). After 24 h, the medium with CaPO4
was replaced with DMEM plus 15% fetal calf serum, 1% antibi-
otics, and 0.5 mg/ml G418 sulfate (Gibco/BRL). Cells containing
the pCI-Phe construct were selected with G418 for a duration of
2 weeks. Resistant cells were replated at low dilution and grown
for 15 days in medium containing G418 when colonies from
single cell clones were harvested and expanded to produce cell
lines.
Transfection and selection of drug-resistant colonies
The procedure used for complementation of the defective
HIV provirus, psHIV-Phe has been previously described
(Yu and Morrow, 1999, 2000, 2001). Briefly, Mammalian
Transfection Kit (Stratagene) was used for cotransfection of
plasmid DNA (pLGRNL, psHIV-Phe or pHGWT, and pTA-
Phe or pCI-Phe) into 293T cells. For complementation in
yeast tRNAPhe cell lines; cell lines were cotransfected with
pLGRNL and psHIVphe or pHgWT. At 48 h posttransfec-
tion, the supernatants were collected and filtered through a
0.45-m pore-size/low-protein binding filter (Pall Gelman
Laboratory, Ann Arbor, MI). Virus production was moni-
tored by p24 antigen levels using a commercial ELISA kit
(Beckman Coulter, Miami, FL). Different dilutions of vi-
ruses as measured by p24 produced by cotransfections were
used to infect HeLa H1 cells. At 12 h after infection, the
cells were washed with phosphate-buffered saline (PBS)
and placed under selection with DMEM-XM media
[DMEM containing 10% FCS, 1% antibiotics, 20 mM
Hepes (pH 7.5), 250 g/ml xanthine, and 50 g/ml myco-
phenolic acid]. The media was replaced every 3 days until
colonies of drug-resistant cells were formed (10–14 days).
Cell colonies were fixed with 5% TCA and stained with 2%
Coomasie blue and number of drug-resistant colonies
counted.
RNA isolation and analysis
Tri-Reagent (Sigma, St. Louis, MD) was used for the
collection of total cellular RNA from yeast tRNAPhe cell
lines and from 293T cells 48 h posttransfection with varied
concentrations of pCI-Phe according to manufacturer’s in-
structions. For RNA isolation from virions, 293T cells were
cotransfected as previously described and resultant viruses
were collected and filtered 48 h posttransfection. The num-
bers of virions were normalized by p24 and virion associ-
ated RNA was isolated via phenol/chloroform extraction.
Prior to Northern blot analysis, residual plasmid DNA was
removed from total RNA samples isolated from 293T cells
transfected with varied concentrations of pCI-Phe via di-
gestion with DNAfree (Ambion, Austin, TX) according to
manufacturers instructions. For Northern blot analysis, oli-
gonucleotide probes were designed to be complementary to
yeast tRNAPhe and mammalian tRNALys,3: tRNALys,3 probe
oligo [5-CGCCCGAACAGGGACTTGAACCCTGGACC-
CTCAGATTAA AAGTCTGATGCTCTACCGACTGAGC-
TATCC-3] and tRNAPhe probe oligo [5-TGCGAATTCTGT
GGATCGAACACAGGACCTCCAGATCTTCAGTCTGGC-
GCTCTCCCAACTGAGCTAAATCC-3]. The probes were
then 5 end-labeled with [-32P]ATP using Ready-To-Go T4
polynucleotide kinase (Amersham Pharmacia Biotech, Piscat-
away, NJ). Free nucleotides were removed by centrifugation
through ProbeQuant G-50 Micro Columns (Amersham Bio-
sciences, Piscataway, NJ); equal amounts of (15 pmol) of
probes were used for each blot (106 cpm/pmol). The North-
ernMax-Gly kit (Ambion) was used according to manufactur-
er’s instructions for Northern blotting and BrightStar-Plus
(Ambion) was used as the positively charged nylon membrane.
Blots were exposed on a phosphor screen and analyzed with a
Phosphorimager. The percentage of yeast tRNAPhe relative to
that of tRNALys,3 in the same cell line was determined by
volume analysis using ImageQuant v1.2 (Molecular Dynam-
ics/Amersham Biosciences, Piscataway, NJ).
Assessment of tRNA aminoacylation status
To analyze the aminoacylation status of tRNAs, cyto-
plasmic RNA was isolated as previously described from
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Hela H1 cells 48 h posttransfection with pTA-Phe or from
cell lines producing yeast tRNAPhe (Ho and Kan, 1987). The
cytoplasmic RNA was separated on an 8% polyacryl-
amide/8 M urea gel buffered with 0.1 M sodium acetate (pH
5) run at 400 V overnight at 4°C. The gel was soaked in 50
mM sodium acetate (pH 4.0) for 30 min and then transferred
to BrightStar-Plus (Ambion) positively charged nylon mem-
brane by downward transfer with 50 mM sodium acetate
(pH 4.0) as a transfer buffer. The Northern blot and oligo-
nucleotide probing was carried out as for total tRNA. For
free tRNA (nonaminoacylated) controls, an aliquot of the
tRNA was deacylated by incubation in 0.1 M Tris (pH 9.0)
for 1 h at 37°C (Ho and Kan, 1987).
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